LFWD icon

ReWalk Robotics

1.77 USD
+0.07
4.12%
Updated Apr 1, 3:59 PM EDT
1 day
4.12%
5 days
-2.21%
1 month
5.99%
3 months
-20.63%
6 months
-43.27%
Year to date
-20.63%
1 year
-65.16%
5 years
-41.58%
10 years
-99.92%
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

195% more call options, than puts

Call options by funds: $56K | Put options by funds: $19K

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

10% more funds holding

Funds holding: 21 [Q3] → 23 (+2) [Q4]

4.1% less ownership

Funds ownership: 7.1% [Q3] → 3.0% (-4.1%) [Q4]

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

77% less capital invested

Capital invested by funds: $2.03M [Q3] → $458K (-$1.57M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$4
126%
upside
Avg. target
$9
408%
upside
High target
$13
634%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Lake Street
Ben Haynor
44% 1-year accuracy
4 / 9 met price target
126%upside
$4
Buy
Maintained
11 Mar 2025
HC Wainwright & Co.
Swayampakula Ramakanth
22% 1-year accuracy
45 / 203 met price target
634%upside
$13
Buy
Reiterated
11 Mar 2025
Laidlaw & Co.
Yale Jen
50% 1-year accuracy
3 / 6 met price target
465%upside
$10
Buy
Initiated
10 Feb 2025

Financial journalist opinion

Based on 7 articles about LFWD published over the past 30 days

Neutral
Zacks Investment Research
2 weeks ago
Lifeward Stock Falls Despite FDA Clearance of ReWalk 7 Exoskeleton
LFWD secures FDA clearance for its ReWalk 7 Exoskeleton, introducing enhanced features to empower individuals with spinal cord injury and expand mobility options.
Lifeward Stock Falls Despite FDA Clearance of ReWalk 7 Exoskeleton
Neutral
GlobeNewsWire
2 weeks ago
FDA Issues Clearance for ReWalk 7 Exoskeleton
Seventh Generation of Industry-Leading Exoskeleton Includes New and Enhanced Features for Individuals with Spinal Cord Injury Seventh Generation of Industry-Leading Exoskeleton Includes New and Enhanced Features for Individuals with Spinal Cord Injury
FDA Issues Clearance for ReWalk 7 Exoskeleton
Neutral
Seeking Alpha
3 weeks ago
Lifeward Ltd. (LFWD) Q4 2024 Earnings Call Transcript
Lifeward Ltd. (NASDAQ:LFWD ) Q4 2024 Earnings Conference Call March 7, 2025 8:30 AM ET Company Participants Mike Lawless - CFO Larry Jasinski - CEO Almog Adar - VP, Finance Conference Call Participants Yale Jen - Laidlaw & Company Ben Haynor - Lake Street Capital Markets Swayampakula Ramakanth - H.C.
Lifeward Ltd. (LFWD) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
3 weeks ago
Lifeward (LFWD) Reports Q4 Loss, Tops Revenue Estimates
Lifeward (LFWD) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.35 per share a year ago.
Lifeward (LFWD) Reports Q4 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
3 weeks ago
Lifeward Ltd. Reports Fourth Quarter and Full Year 2024 Financial Results
Record quarterly and annual revenue of $7.5M and $25.7M, respectively Continued strong growth in U.S. pipeline of ReWalk opportunities with over 110 qualified leads in process Strategic s hift t owards p rofitability: 2025 Sustainable Growth Plan f ocuses on growth of c ore p roduct l ines with a s treamlined c ost s tructure and r educed o perating loss MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Lifeward Ltd. Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
GlobeNewsWire
3 weeks ago
Lifeward and CorLife Finalize Partnership to Expand Workers' Compensation Access to ReWalk Exoskeleton
CorLife to become the exclusive distributor of the ReWalk Personal Exoskeleton for individuals with Workers' Compensation claims
Lifeward and CorLife Finalize Partnership to Expand Workers' Compensation Access to ReWalk Exoskeleton
Neutral
GlobeNewsWire
3 weeks ago
Lifeward and MYOLYN Expand Partnership to Enhance Patient Access to MyoCycle FES Cycling Therapy System for Home Use
New Agreement Expands Distribution Rights to Lifeward to Include Referral Sales for Home Use Applications New Agreement Expands Distribution Rights to Lifeward to Include Referral Sales for Home Use Applications
Lifeward and MYOLYN Expand Partnership to Enhance Patient Access to MyoCycle FES Cycling Therapy System for Home Use
Neutral
GlobeNewsWire
1 month ago
Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and fiscal year-end financial results before the markets open on Friday, March 7, 2025.
Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025
Neutral
GlobeNewsWire
1 month ago
Lifeward Announces CEO Transition
CEO Larry Jasinski to Retire Company Begins Search for New Leader to Drive Next Phase of Growth Company Provides Preliminary Full-Year 2024 Revenue Reschedules Virtual Investor Event Until Later in 2025 After Hiring of New CEO MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Lifeward Announces CEO Transition
Neutral
GlobeNewsWire
2 months ago
Lifeward CEO Issues Year-End 2024 Open Letter to Shareholders and Provides 2025 Commercial and Operational Priorities
With recent financing and current capital, the Company believes it has sufficient cash to pursue its goals With recent financing and current capital, the Company believes it has sufficient cash to pursue its goals
Lifeward CEO Issues Year-End 2024 Open Letter to Shareholders and Provides 2025 Commercial and Operational Priorities
Charts implemented using Lightweight Charts™